Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Free Cash Flow (2016 - 2025)

Assembly Biosciences has reported Free Cash Flow over the past 11 years, most recently at $14.2 million for Q4 2025.

  • Quarterly results put Free Cash Flow at $14.2 million for Q4 2025, up 3592.14% from a year ago — trailing twelve months through Dec 2025 was -$41.2 million (up 19.52% YoY), and the annual figure for FY2025 was -$41.2 million, up 19.52%.
  • Free Cash Flow for Q4 2025 was $14.2 million at Assembly Biosciences, up from -$15.2 million in the prior quarter.
  • Over the last five years, Free Cash Flow for ASMB hit a ceiling of $73.6 million in Q4 2023 and a floor of -$36.4 million in Q1 2021.
  • Median Free Cash Flow over the past 5 years was -$18.1 million (2022), compared with a mean of -$12.5 million.
  • Biggest five-year swings in Free Cash Flow: tumbled 277.36% in 2021 and later surged 3592.14% in 2025.
  • Assembly Biosciences' Free Cash Flow stood at -$19.4 million in 2021, then increased by 0.65% to -$19.3 million in 2022, then surged by 482.13% to $73.6 million in 2023, then plummeted by 100.55% to -$407000.0 in 2024, then surged by 3592.14% to $14.2 million in 2025.
  • The last three reported values for Free Cash Flow were $14.2 million (Q4 2025), -$15.2 million (Q3 2025), and -$16.8 million (Q2 2025) per Business Quant data.